AstraZeneca shares underperform broad pharma index by 10% by Dec 31 2…

AstraZeneca’s stock decline following its trial failure signals investor skepticism about its pipeline reliability. If additional pipeline setbacks occur or valuation premiums contract further, shares could lag peers.

price · Prediction Market

Implied probability (Yes)

70%

Closes

2026-12-31

More price markets

• Samsung Electronics market cap to exceed $1.2T by Q3 2026 — 78% Yes
• Cisco stock to rise above $65 by Q3 2026 — 72% Yes
• Private jet charter prices increase 20% in 2027 — 75% Yes
• Google Messages sees 30% user growth in 6 months post-launch — 70% Yes
• US AI chip ETF doubles in value by 2026-09-30 — 65% Yes
• X’s stock price rises 10% within 3 months of History tab launch — 55% Yes
• TSK enters top 5 Spanish engineering firms by market cap — 60% Yes
• Ford stock volatility exceeds 60% annualized within 6 months — 75% Yes

Browse all price markets →